Ibutamoren MesylateGrowth hormone (GH) secretagogue CAS# 159752-10-0 |
- Anamorelin
Catalog No.:BCC1362
CAS No.:249921-19-5
- Anamorelin Fumarate
Catalog No.:BCC1363
CAS No.:339539-92-3
- Anamorelin hydrochloride
Catalog No.:BCC1364
CAS No.:861998-00-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 159752-10-0 | SDF | Download SDF |
PubChem ID | 6450830 | Appearance | Powder |
Formula | C28H40N4O8S2 | M.Wt | 624.77 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | MK-677;Crescendo;MK 0677;MK-0677;MK0677 | ||
Solubility | DMSO : 50 mg/mL (80.03 mM; Need ultrasonic) H2O : ≥ 50 mg/mL (80.03 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid | ||
SMILES | CC(C)(C(=O)NC(COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O | ||
Standard InChIKey | DUGMCDWNXXFHDE-VZYDHVRKSA-N | ||
Standard InChI | InChI=1S/C27H36N4O5S.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);1H3,(H,2,3,4)/t22-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | High affinity ghrelin receptor agonist (pKi = 8.14). Growth hormone (GH) secretagog; stimulates GH release from rat pituitary cells in vitro (EC50 = 1.3 nM) and enhances GH plasma levels in vivo. Also attenuates isoproterenol -induced lipolysis in rat adipocytes in vitro. Orally bioavailable. |
Ibutamoren Mesylate Dilution Calculator
Ibutamoren Mesylate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL | 32.0118 mL | 40.0147 mL |
5 mM | 0.3201 mL | 1.6006 mL | 3.2012 mL | 6.4024 mL | 8.0029 mL |
10 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL | 3.2012 mL | 4.0015 mL |
50 mM | 0.032 mL | 0.1601 mL | 0.3201 mL | 0.6402 mL | 0.8003 mL |
100 mM | 0.016 mL | 0.08 mL | 0.1601 mL | 0.3201 mL | 0.4001 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue. Ibutamoren mesylate (MK-0677) stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor. MK-677is a drug which acts as a potent, orally active growth hormone secretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels. It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. Ibutamoren mesylate (MK-0677) also alters metabolism of body fat and so may have application in the treatment of obesity.
- ISRIB (trans-isomer)
Catalog No.:BCC5340
CAS No.:1597403-47-8
- Wikstrol A
Catalog No.:BCN7938
CAS No.:159736-35-3
- Saropyrone
Catalog No.:BCN7692
CAS No.:159650-12-1
- 3,4-Secotirucalla-4(28,7,24-triene-3),26-dioic acid
Catalog No.:BCN1549
CAS No.:159623-48-0
- Daminozide
Catalog No.:BCC1514
CAS No.:1596-84-5
- GR 55562 dihydrochloride
Catalog No.:BCC6913
CAS No.:159533-25-2
- Fluconazole mesylate
Catalog No.:BCC4236
CAS No.:159532-41-9
- Enfuvirtide
Catalog No.:BCC5641
CAS No.:159519-65-0
- N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu
Catalog No.:BCC5853
CAS No.:159439-02-8
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- MPDC
Catalog No.:BCC6873
CAS No.:159262-32-5
- PNU 22394 hydrochloride
Catalog No.:BCC7285
CAS No.:15923-42-9
- Fmoc-Lys(Ac)-OH
Catalog No.:BCC3514
CAS No.:159766-56-0
- Ulipristal
Catalog No.:BCC4944
CAS No.:159811-51-5
- Sikokianin C
Catalog No.:BCN6827
CAS No.:159813-69-1
- 4'-O-Methylirenolone
Catalog No.:BCN7174
CAS No.:159853-36-8
- Mc-Val-Cit-PABC-PNP
Catalog No.:BCC4028
CAS No.:159857-81-5
- 3,5-Di-O-caffeoylquinic acid methyl ester
Catalog No.:BCN6491
CAS No.:159934-13-1
- NIBR189
Catalog No.:BCC8056
CAS No.:1599432-08-2
- Nelfinavir
Catalog No.:BCC4138
CAS No.:159989-64-7
- Nelfinavir Mesylate
Catalog No.:BCC1794
CAS No.:159989-65-8
- Iniparib (BSI-201)
Catalog No.:BCC2208
CAS No.:160003-66-7
- Antibiotic AB 4063B
Catalog No.:BCN1827
CAS No.:160041-33-8
- Sambutoxin
Catalog No.:BCN1709
CAS No.:160047-56-3
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.[Pubmed:21067829]
Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9.
Most elderly patients admitted for hip fracture suffer functional decline. Previous studies with MK-0677 in hip fracture patients suggested possible benefits to functional recovery. This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61). Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood. At 24-weeks, the mean stair climbing power increased by 12.5 W in the MK-0677 group (95% confidence interval (CI) = -10.95-35.88; p = 0.292) compared with placebo. Gait speed increased by a 0.7-score difference in the means (95% CI = 0.17-1.28; p = 0.011). There was no improvement in MK-0677 treated patients in several other functional performance measures. The MK-0677 group experienced fewer falls during the study compared to placebo and smaller number of patients who had any falls (p = 0.096). Levels of IGF-1 in treated patients increased by 51.4 ng/ml (95% CI = 34.42-68.44; p < 0.001) compared to placebo. Trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients. In hip fracture patients treated with 25mg/day MK-0677, the increase in plasma IGF-1 levels was not paralleled by improvement in most functional performance measures. MK-0677 has an unfavorable safety profile in this patient population.
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.[Pubmed:11452249]
Clin Pharmacol Ther. 2001 Jul;70(1):91-8.
Ibutamoren Mesylate (MK-0677), an orally active nonpeptide growth hormone (GH) secretagogue, stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor. We evaluated the safety and tolerability and the GH-insulin-like growth factor (IGF) responses to two dosages of oral Ibutamoren Mesylate given to children with GH deficiency for 7 to 8 days. The patients, 18 prepubertal children (15 male, 3 female) with idiopathic GH deficiency, had a chronologic age of 10.6 +/- 0.8 years (mean +/- SD), bone age of 7.4 +/- 0.7 years, growth velocity < 10th percentile for age, height < 10th percentile for age, and a maximum GH response of < or = 10 microg/L to two different GH stimulation tests. The children were assigned as follows to one of three treatment groups with Ibutamoren Mesylate: 0.2 mg/kg per day for 7 days (days 1-7 or 8-14) and matching placebo for the alternate 7 days (groups I and II, respectively) or 0.8 mg/kg per day for 7 days (days 8-14, group III). On day 15 all patients received an 0.8-mg/kg dose of Ibutamoren Mesylate. Patients in groups I and II were studied first to assess safety at the low dose before advancement to the high dose. Hormonal profiles were evaluated on day -1 (baseline) and day 15, and the results were expressed as the change from baseline within each group. After administration of Ibutamoren Mesylate 0.8 mg/kg for 8 days (group III), the median increases (on day 15) from baseline were as follows: 3.8 microg/L (range, 0 to 34.3) for serum GH peak concentration (P = .001), 4.3 microg x h/L (range, 1.3 to 35.6) for the GH area under the concentration-time curve from time zero to 8 hours (AUC(0-8)) (P < .001), 12 microg/L (range, -4 to 116) for serum IGF-I (P = .01), and 0.4 microg/L (range, -0.9 to 1.5) for serum IGF-binding protein 3 (IGFBP-3) (P = .01). There was no change in serum prolactin, glucose, triiodothyronine, thyroxine, thyrotropin, peak serum cortisol, and insulin concentrations or 24-hour urinary free cortisol after administration of 0.8 mg/kg per day of Ibutamoren Mesylate for 8 days. We conclude that short-term administration of Ibutamoren Mesylate can increase GH, IGF-I, and IGFBP-3 levels in some children with GH deficiency. Thus this compound is applicable for testing its effect on growth velocity.
Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor.[Pubmed:19625579]
Mol Pharmacol. 2009 Oct;76(4):802-11.
Some growth hormone secretagogues act as agonists at the ghrelin receptor and have been described as "ago-allosteric" ligands because of an ability to also modulate the maximum efficacy and potency of ghrelin (Holst et al., 2005). In membranes prepared from cells coexpressing the human ghrelin receptor and the G protein Galpha(o1), N-[1(R)-1, 2-dihydro-1-ethanesulfonylspiro-3H-indole-3,4'-piperidin)-1'-yl]carbonyl-2-(pheny lmethoxy)-ethyl-2-amino-2-methylpropanamide (MK-677), growth hormone-releasing peptide 6 (GHRP-6), and the 2(R)-hydroxypropyl derivative of 3-amino-3-methyl-N-(2,3,4,5-tetrahydro-2-oxo-1-([2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl)-1H-1-benzazepin-3(R)-yl)-butanamide (L-692,585) each functioned as direct agonists, and each displayed higher efficacy than ghrelin. The effect of multiple, fixed concentrations of each of these ligands on the function and concentration-dependence of ghrelin and the effect of multiple, fixed concentrations of ghrelin on the action of MK-677, GHRP-6, and L-692,585 was analyzed globally according to a modified version of an operational model of allosterism that accounts for allosteric modulation of affinity, efficacy, and allosteric agonism. Each of the data sets was best fit by a model of simple competition between a partial and a full agonist. Both positive and negative allosteric modulators are anticipated to alter the kinetics of binding of an orthosteric agonist. However, none of the proposed ago-allosteric regulators tested had any effect on the dissociation kinetics of (125)I-[His]-ghrelin, and GHRP-6 and MK-677 were able to fully displace (125)I-[His]-ghrelin from the receptor. At least in the system tested, each of the ligands acted in a simple competitive fashion with ghrelin as demonstrated by analysis according to a model whereby ghrelin is a partial agonist with respect to each of the synthetic agonists tested.
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor.[Pubmed:15363972]
Eur J Pharmacol. 2004 Sep 13;498(1-3):27-35.
Besides possessing a strong growth hormone (GH)-releasing activity, the gastrointestinal octanoylated peptide ghrelin has been reported to antagonize lipolysis in rat adipocytes. It is not yet clear whether this inhibitory activity on lipolysis is also shared by the major circulating isoform, des-acyl ghrelin, that does not activate the ghrelin receptor, namely the type 1a GH secretagogue-receptor (GHS-R1a) and lacks the endocrine effects of the acylated form. Here we show that des-acyl ghrelin, like ghrelin and some synthetic GHS (hexarelin and MK0677) and carboxy-terminally ghrelin fragments such as ghrelin-(1-5) and ghrelin-(1-10), all significantly reduced, over concentrations ranging from 1 to 1000 nM, the stimulation of glycerol release caused in rat epididymal adipocytes by the nonselective beta-adrenoceptor agonist isoproterenol in vitro. The order of potency on stimulated-lipolysis was: des-acyl ghrelin=ghrelin>MK0677=hexarelin>ghrelin-(1-5)=ghrelin-(1-10). This ranking was consistent with the binding experiments performed on membranes of epididymal adipose tissue or isolated adipocytes that did not express mRNA for GHS-R1a. A common high-affinity binding site was recognized in these cells by both acylated and des-acylated ghrelin and also by hexarelin, MK0677, ghrelin-(1-5) and ghrelin-(1-10). In conclusion, these findings provide the first evidence that des-acyl ghrelin, as well as ghrelin, short ghrelin fragments and synthetic GHS, may act directly as antilipolytic factors on the adipose tissue through binding to a specific receptor which is distinct from GHS-R1a.
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.[Pubmed:7624358]
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.